Zaire Ebola virus


Alias: Zaire ebolavirus, ZEBOV

Top Publications

  1. Bavari S, Bosio C, Wiegand E, Ruthel G, Will A, Geisbert T, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med. 2002;195:593-602 pubmed
  2. Kiley M, Cox N, Elliott L, Sanchez A, deFries R, Buchmeier M, et al. Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. J Gen Virol. 1988;69 ( Pt 8):1957-67 pubmed
    ..In addition, these studies confirm the belief that MBG and EBO viruses are members of the new virus family, the Filoviridae. ..
  3. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology. 2000;278:20-6 pubmed
    ..We suggest that integrins, especially the beta1 group, might interact with the GP and perhaps be involved in Ebola virus entry into cells. ..
  4. Sullivan N, Peterson M, Yang Z, Kong W, Duckers H, Nabel E, et al. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol. 2005;79:547-53 pubmed
    ..By altering the trafficking of select cellular proteins, Ebola virus GP inflicts cell damage and may facilitate immune escape by the virus. ..
  5. Reid S, Leung L, Hartman A, Martinez O, Shaw M, Carbonnelle C, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006;80:5156-67 pubmed
    ..These data suggest that VP24 is likely to be an important virulence determinant that allows EBOV to evade the antiviral effects of IFNs. ..
  6. Licata J, Simpson Holley M, Wright N, Han Z, Paragas J, Harty R. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol. 2003;77:1812-9 pubmed
    ..These results provide important insights into the complex interplay between viral and host proteins during the late stages of Ebola virus budding. ..
  7. Watanabe S, Noda T, Kawaoka Y. Functional mapping of the nucleoprotein of Ebola virus. J Virol. 2006;80:3743-51 pubmed
    ..These data advance our understanding of the functional region(s) of Ebola virus NP, which in turn should improve our knowledge of the Ebola virus life cycle and its extreme pathogenicity. ..
  8. Noda T, Watanabe S, Sagara H, Kawaoka Y. Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus. J Virol. 2007;81:3554-62 pubmed
    ..These findings enhance our understanding of Ebola virus assembly and in so doing move us closer to the identification of targets for the development of antiviral compounds to combat Ebola virus infection. ..
  9. Harty R, Brown M, Wang G, Huibregtse J, Hayes F. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A. 2000;97:13871-6 pubmed
    ..Last, these studies imply that VP40 likely plays an important role in filovirus budding, and that budding of retroviruses, rhabdoviruses, and filoviruses may proceed via analogous mechanisms. ..

More Information

Publications105 found, 100 shown here

  1. Feldmann H, Volchkov V, Volchkova V, Stroher U, Klenk H. Biosynthesis and role of filoviral glycoproteins. J Gen Virol. 2001;82:2839-48 pubmed
  2. Timmins J, Schoehn G, Ricard Blum S, Scianimanico S, Vernet T, Ruigrok R, et al. Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J Mol Biol. 2003;326:493-502 pubmed
    ..These results suggest that hNedd4 and Tsg101 may play complimentary roles at a late stage of the assembly process, by recruiting cellular factors of two independent pathways to the site of budding at the plasma membrane. ..
  3. Kallstrom G, Warfield K, Swenson D, Mort S, Panchal R, Ruthel G, et al. Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods. 2005;127:1-9 pubmed
    ..Furthermore, this assay can be used in surrogate models in non-biocontainment environment, facilitating both basic research on the mechanism of EBOV assembly and budding as well as drug-discovery research. ..
  4. Wahl Jensen V, Afanasieva T, Seebach J, Stroher U, Feldmann H, Schnittler H. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol. 2005;79:10442-50 pubmed
    ..Furthermore, sGP, the major soluble glycoprotein of Ebola virus, seems to possess an anti-inflammatory role by protecting the endothelial cell barrier function. ..
  5. Alazard Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, Ottmann M, et al. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol. 2006;87:1247-57 pubmed
    ..These findings indicate that the synthesis of EBOV GP in virus-infected cells is controlled well by several mechanisms that do not allow GP overexpression and hence the early appearance of its cytotoxic properties. ..
  6. Cardenas W, Loo Y, Gale M, Hartman A, Kimberlin C, Martinez Sobrido L, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol. 2006;80:5168-78 pubmed
    ..These data support the hypothesis that dsRNA binding may contribute to VP35 IFN antagonist function. However, additional mechanisms of inhibition, at a point proximal to the IRF-3 kinases, most likely also exist. ..
  7. Yang Z, Duckers H, Sullivan N, Sanchez A, Nabel E, Nabel G. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000;6:886-9 pubmed
    ..These findings indicate that GP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection...
  8. Dessen A, Volchkov V, Dolnik O, Klenk H, Weissenhorn W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J. 2000;19:4228-36 pubmed
    ..The crystal structure reveals how the molecule may be able to switch from a monomeric conformation to a hexameric form, as observed in vitro. Its implications for the assembly process are discussed. ..
  9. Jasenosky L, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol. 2001;75:5205-14 pubmed
    ..These data suggest that VP40 binds the lipid bilayer in an efficient yet structurally complex fashion. ..
  10. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol. 2002;76:406-10 pubmed
  11. Basler C, Mikulasova A, Martinez Sobrido L, Paragas J, Mühlberger E, Bray M, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 2003;77:7945-56 pubmed
    ..These data suggest that in Ebola virus-infected cells, VP35 inhibits the induction of antiviral genes, including the IFN-beta gene, by blocking IRF-3 activation. ..
  12. Panchal R, Ruthel G, Kenny T, Kallstrom G, Lane D, Badie S, et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A. 2003;100:15936-41 pubmed
    ..We also report the successful application of the biarsenic fluorophore, FlAsH, combined with a tetracysteine tag for imaging of Ebola VP40 in live cells. ..
  13. Ruthel G, Demmin G, Kallstrom G, Javid M, Badie S, Will A, et al. Association of ebola virus matrix protein VP40 with microtubules. J Virol. 2005;79:4709-19 pubmed
    ..These results suggest that microtubules may play an important role in the Ebola virus life cycle and potentially provide a novel target for therapeutic intervention against this highly pathogenic virus. ..
  14. Neumann G, Ebihara H, Takada A, Noda T, Kobasa D, Jasenosky L, et al. Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol. 2005;79:10300-7 pubmed
    ..These findings indicate that the Ebola VP40 late domain motifs enhance virus replication but are not absolutely required for virus replication in cell culture. ..
  15. Kash J, M hlberger E, Carter V, Grosch M, Perwitasari O, Proll S, et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol. 2006;80:3009-20 pubmed publisher
    ..expression by characterizing the regulation of gene expression responses in human liver cells infected with Zaire Ebolavirus (ZEBOV), Reston Ebolavirus (REBOV), and Marburgvirus (MARV), using transcriptional profiling and ..
  16. Leung L, Park M, Martinez O, Valmas C, LOPEZ C, Basler C. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol. 2011;89:792-802 pubmed publisher
    ..However, cells that utilize the TLR pathway can circumvent this inhibition, suggesting that the presence of multiple viral sensors enables the host to overcome viral immune evasion mechanisms. ..
  17. Feldmann H, Kiley M. Classification, structure, and replication of filoviruses. Curr Top Microbiol Immunol. 1999;235:1-21 pubmed
  18. Maruyama T, Rodriguez L, Jahrling P, Sanchez A, Khan A, Nichol S, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999;73:6024-30 pubmed
    ..The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection...
  19. Wilson J, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn A, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664-6 pubmed
    ..The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus. ..
  20. Basler C, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk H, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000;97:12289-94 pubmed
    ..The Ebola virus VP35 therefore is likely to inhibit induction of type I IFN in Ebola virus-infected cells and may be an important determinant of Ebola virus virulence in vivo. ..
  21. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002;76:4855-65 pubmed
    ..These results demonstrated the central role of VP40 in formation of the filamentous structure of Ebola virions and may suggest an interaction between VP40 and GP in morphogenesis. ..
  22. Huang Y, Xu L, Sun Y, Nabel G. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell. 2002;10:307-16 pubmed
    ..This distinct mechanism of regulation for filovirus assembly suggests new approaches for viral therapies and vaccines for Ebola and related viruses. ..
  23. Han Z, Boshra H, Sunyer J, Zwiers S, Paragas J, Harty R. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol. 2003;77:1793-800 pubmed
    ..These data indicate that VP24 possesses structural features commonly associated with viral matrix proteins and that VP24 may have a role in virus assembly and budding...
  24. Warfield K, Bosio C, Welcher B, Deal E, Mohamadzadeh M, Schmaljohn A, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A. 2003;100:15889-94 pubmed
    ..Together, our data suggest that eVLPs represent a promising vaccine candidate for protection against Ebola virus infections and a much needed tool to examine the genesis and nature of immune responses to Ebola virus. ..
  25. Licata J, Johnson R, Han Z, Harty R. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol. 2004;78:7344-51 pubmed
    ..the C-terminal 50 amino acids of NP may be important for interacting with and enhancing release of VP40 VLPs. These findings provide a more complete understanding of the role of VP40 and additional Ebola virus proteins during budding. ..
  26. Enterlein S, Warfield K, Swenson D, Stein D, Smith J, Gamble C, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006;50:984-93 pubmed
    ..Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates. ..
  27. Hartman A, Dover J, Towner J, Nichol S. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol. 2006;80:6430-40 pubmed
    The VP35 protein of Zaire Ebola virus is an essential component of the viral RNA polymerase complex and also functions to antagonize the cellular type I interferon (IFN) response by blocking activation of the transcription factor IRF-3...
  28. Reid S, Valmas C, Martinez O, Sanchez F, Basler C. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol. 2007;81:13469-77 pubmed
    The Zaire ebolavirus protein VP24 was previously demonstrated to inhibit alpha/beta interferon (IFN-alpha/beta)- and IFN-gamma-induced nuclear accumulation of tyrosine-phosphorylated STAT1 (PY-STAT1) and to inhibit IFN-alpha/beta- and IFN-..
  29. Mateo M, Reid S, Leung L, Basler C, Volchkov V. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol. 2010;84:1169-75 pubmed publisher
    ..We demonstrate that loss of function correlates with loss of binding to KPNalpha proteins. Thus, the VP24 IFN antagonist function requires the ability of VP24 to interact with KPNalpha. ..
  30. Leung D, Prins K, Borek D, Farahbakhsh M, Tufariello J, Ramanan P, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol. 2010;17:165-72 pubmed publisher
    ..These results suggest that simultaneous recognition of dsRNA backbone and blunt ends provides a mechanism by which Ebola VP35 antagonizes host dsRNA sensors and immune responses. ..
  31. Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, Theriault S, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006;2:e73 pubmed publisher
    b>Zaire ebolavirus (ZEBOV) causes severe hemorrhagic fever in humans and nonhuman primates, with fatality rates in humans of up to 90%. The molecular basis for the extreme virulence of ZEBOV remains elusive...
  32. Falzarano D, Krokhin O, Van Domselaar G, Wolf K, Seebach J, Schnittler H, et al. Ebola sGP--the first viral glycoprotein shown to be C-mannosylated. Virology. 2007;368:83-90 pubmed
    ..In this regard, C-mannosylation of sGP may be an anomaly resulting from the unique manner in which this protein is generated as the product of unedited transcripts from the glycoprotein gene of Ebola. ..
  33. Gregory S, Larsson P, Nelson E, Kasson P, White J, Tamm L. Ebolavirus entry requires a compact hydrophobic fist at the tip of the fusion loop. J Virol. 2014;88:6636-49 pubmed publisher
    ..We determined structures of the Ebolavirus fusion loop and found residues critical for forming a consolidated hydrophobic surface, membrane insertion, and viral entry. ..
  34. Noda T, Hagiwara K, Sagara H, Kawaoka Y. Characterization of the Ebola virus nucleoprotein-RNA complex. J Gen Virol. 2010;91:1478-83 pubmed publisher
    ..These findings enhance our knowledge of Ebola virus assembly and understanding of the Ebola virus life cycle...
  35. Mehedi M, Falzarano D, Seebach J, Hu X, Carpenter M, Schnittler H, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011;85:5406-14 pubmed publisher
    ..While ssGP appears to share similar structural properties with sGP, it does not appear to have the same anti-inflammatory function on endothelial cells as sGP...
  36. Yen B, Mulder L, Martinez O, Basler C. Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol. 2014;88:12500-10 pubmed publisher
    b>Zaire ebolavirus (EBOV) VP35 is a double-stranded RNA (dsRNA)-binding protein that inhibits RIG-I signaling and alpha/beta interferon (IFN-α/β) responses by both dsRNA-binding-dependent and -independent mechanisms...
  37. Medaglini D, Harandi A, Ottenhoff T, Siegrist C. Ebola vaccine R&D: Filling the knowledge gaps. Sci Transl Med. 2015;7:317ps24 pubmed publisher
    ..the VSV-EBOVAC project harnesses state-of-the-art technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine and ensures that such information is shared among stakeholders.
  38. McCarthy S, Majchrzak Kita B, Racine T, Kozlowski H, Baker D, Hoenen T, et al. A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Negl Trop Dis. 2016;10:e0004364 pubmed publisher
    ..several 2 and 3 drug combinations with strong anti-Ebola activity, confirmed in studies using fully infectious ZEBOV, providing a rationale for testing combination therapies in animal models of lethal Ebola challenge...
  39. Wang B, Wang Y, Frabutt D, Zhang X, Yao X, Hu D, et al. Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. J Biol Chem. 2017;292:5860-5870 pubmed publisher
    ..Together, we conclude that, although Asn563 and Asn618 are not required for EBOV GP expression, they synergistically regulate its maturation, which determines its functionality. ..
  40. Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, et al. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Rep. 2017;20:2251-2261 pubmed publisher identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell ..
  41. Feldmann H, Nichol S, Klenk H, Peters C, Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994;199:469-73 pubmed publisher
    ..These data, together with prior findings, indicate that the genus Filovirus can be divided into a MBG group and EBO group...
  42. Volchkova V, Klenk H, Volchkov V. Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology. 1999;265:164-71 pubmed publisher
    ..Both cleavage fragments contain sialic acid, but only Delta-peptide is highly O-glycosylated...
  43. Reid S, C rdenas W, Basler C. Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology. 2005;341:179-89 pubmed publisher
  44. Kuhn J, Radoshitzky S, Guth A, Warfield K, Li W, Vincent M, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem. 2006;281:15951-8 pubmed publisher
    ..An homologous 148-amino acid fragment of the Zaire ebolavirus GP1 subunit similarly bound the same cell lines more efficiently than a series of longer GP1 truncation ..
  45. Mart nez M, Biedenkopf N, Volchkova V, Hartlieb B, Alazard Dany N, Reynard O, et al. Role of Ebola virus VP30 in transcription reinitiation. J Virol. 2008;82:12569-73 pubmed publisher
    ..We demonstrate that VP30 is involved in reinitiation of gene transcription and that this activity is affected by mutations at the phosphorylation sites...
  46. Dapiaggi F, Pieraccini S, Sironi M. In silico study of VP35 inhibitors: from computational alanine scanning to essential dynamics. Mol Biosyst. 2015;11:2152-7 pubmed publisher
    ..Moreover we characterized the dynamics of the complexes, showing that the presence of ligands modifies the overall protein dynamics as well as the behavior of particular protein segments. ..
  47. Ren J, Zhang R, Zhang H, Cao X, Liu L, Xie Y. Identification of novel VP35 inhibitors: Virtual screening driven new scaffolds. Biomed Pharmacother. 2016;84:199-207 pubmed publisher
    ..The mapping results of hit compounds onto pharmacophore model and 3D QSAR model, and the molecular interactions of the potential inhibitors with the active site residues have been discussed in detail. ..
  48. Agnandji S, Fernandes J, Bache E, Obiang Mba R, Brosnahan J, Kabwende L, et al. Safety and immunogenicity of rVSV?G-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. PLoS Med. 2017;14:e1002402 pubmed publisher
    The rVSV?G-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data.
  49. Warfield K, Swenson D, Demmin G, Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines. 2005;4:429-40 pubmed publisher
    ..Thus, in addition to their use as a vaccine, VLPs are currently being used as tools to learn lessons about filovirus pathogenesis, immunology, replication and assembly requirements...
  50. Luthra P, Jordan D, Leung D, Amarasinghe G, Basler C. Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis. J Virol. 2015;89:5148-53 pubmed publisher
    ..Mutational analysis demonstrates that VP35 interaction is required for the functional effects of LC8. ..
  51. Wang L, Chen Q, Zhou L, Guo Y. [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro]. Yao Xue Xue Bao. 2015;50:1545-50 pubmed
    ..drugs were screened using the ZEBOV-GP/HIV model, a pseudovirus formed by an HIV-core packed with the Zaire Ebola virus glycoprotein...
  52. Gc J, Pokhrel R, Bhattarai N, Johnson K, Gerstman B, Stahelin R, et al. Graphene-VP40 interactions and potential disruption of the Ebola virus matrix filaments. Biochem Biophys Res Commun. 2017;493:176-181 pubmed publisher
  53. Rampini E, Occella C, Barretta M, Nemelka O, Somenzi M, Persi A, et al. [Josamycin in the treatment of impetigo in childhood: comparison with erythromycin]. G Ital Chemioter. 1982;29 Suppl 1:155-64 pubmed
  54. Bukreyev A, Volchkov V, Blinov V, Netesov S. The VP35 and VP40 proteins of filoviruses. Homology between Marburg and Ebola viruses. FEBS Lett. 1993;322:41-6 pubmed
    ..It is suggested that these sequences are mRNA extremities and at the same time the regulatory elements for mRNA transcription. Homology between the MBG and EBO proteins was discovered. ..
  55. Sanchez A, Yang Z, Xu L, Nabel G, Crews T, Peters C. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol. 1998;72:6442-7 pubmed
    ..We also determined that SGP is secreted from infected cells almost exclusively in the form of a homodimer that is joined by disulfide bonding...
  56. Volchkova V, Feldmann H, Klenk H, Volchkov V. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology. 1998;250:408-14 pubmed publisher
  57. Malashkevich V, Schneider B, McNally M, Milhollen M, Pang J, Kim P. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci U S A. 1999;96:2662-7 pubmed
    ..The Ebo-74 structure likely represents the fusion-active conformation of the protein, and its overall architecture resembles several other viral membrane-fusion proteins, including those from HIV and influenza...
  58. Simmons G, Reeves J, Grogan C, Vandenberghe L, Baribaud F, Whitbeck J, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology. 2003;305:115-23 pubmed
  59. Watanabe S, Watanabe T, Noda T, Takada A, Feldmann H, Jasenosky L, et al. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol. 2004;78:999-1005 pubmed
    ..Thus, this system allows us to study Ebola virus entry, replication, and assembly without biosafety level 4 containment. Furthermore, it may be useful in vaccine production against this highly pathogenic agent...
  60. Wahl Jensen V, Kurz S, Hazelton P, Schnittler H, Str her U, Burton D, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol. 2005;79:2413-9 pubmed publisher
    ..The secreted glycoproteins do not appear to play any role in exogenous activation of these cells during Ebola virus infection...
  61. Han Z, Harty R. Packaging of actin into Ebola virus VLPs. Virol J. 2005;2:92 pubmed publisher
    ..These data suggest that VP40 may interact with cellular actin, and that actin may play a role in assembly and/or budding of Ebola VLPs...
  62. Oswald W, Geisbert T, Davis K, Geisbert J, Sullivan N, Jahrling P, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 2007;3:e9 pubmed publisher
    ..It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody...
  63. Brindley M, Hughes L, Ruiz A, McCray P, Sanchez A, Sanders D, et al. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol. 2007;81:7702-9 pubmed publisher
    ..In total, our study confirms the role of some GP1 residues in EBOV entry that had previously been recognized and identifies for the first time other residues that are important for productive entry...
  64. Freitas M, Gaspar L, Lorenzoni M, Almeida F, Tinoco L, Almeida M, et al. Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts. J Biol Chem. 2007;282:27306-14 pubmed publisher
    ..Our data shed light on the structural "domains" of fusion peptides and provide a clue for the development of a drug that might block the early steps of viral infection...
  65. Yamayoshi S, Kawaoka Y. Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. J Infect Dis. 2007;196 Suppl 2:S291-5 pubmed publisher
    ..We found that the amino acid sequence around the proline at position 53 plays a critical role in VLP production and intracellular transport. These data also may suggest that a novel host factor(s) is involved in virus budding...
  66. Martinez O, Ndungo E, Tantral L, Miller E, Leung L, Chandran K, et al. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner. J Virol. 2013;87:3324-34 pubmed publisher
    b>Zaire Ebola virus (EBOV) is a zoonotic pathogen that causes severe hemorrhagic fever in humans. A single viral glycoprotein (GP) mediates viral attachment and entry...
  67. Ilinykh P, Lubaki N, Widen S, Renn L, Theisen T, Rabin R, et al. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. J Virol. 2015;89:7567-83 pubmed publisher
  68. Shiwani H, Pharithi R, Khan B, Egom C, Kruzliak P, Maher V, et al. An update on the 2014 Ebola outbreak in Western Africa. Asian Pac J Trop Med. 2017;10:6-10 pubmed publisher
    ..Novel techniques for diagnosis are also discussed. Finally, the current research regarding treatment and vaccine development is reviewed, particularly the implementation of rVSV-ZEBOV vaccination programs.
  69. Siqueira A, Jerônimo Lima A, de Souza R, Santos A, da Silva Gonçalves Vianez Júnior J, Gonçalves E. Anti-dengue virus activity of scytovirin and evaluation of point mutation effects by molecular dynamics and binding free energy calculations. Biochem Biophys Res Commun. 2017;490:1033-1038 pubmed publisher
    ..which was isolated from the cyanobacterium Scytonema varium and has proven activity against HIV and Zaire Ebola Virus. To achieve the results presented here, we tested the affinity of full-length scytovirin, SD1 and SD2 ..
  70. Han Z, Licata J, Paragas J, Harty R. Permeabilization of the plasma membrane by Ebola virus GP2. Virus Genes. 2007;34:273-81 pubmed publisher
    ..Together, these data suggest that the TM region of GP2 modifies the permeability of the plasma membrane. These findings may have important implications for GP-induced cell damage and pathogenesis of EBOV infection...
  71. Olal D, Kuehne A, Bale S, Halfmann P, Hashiguchi T, Fusco M, et al. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol. 2012;86:2809-16 pubmed publisher
  72. Takada A, Robison C, Goto H, Sanchez A, Murti K, Whitt M, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A. 1997;94:14764-9 pubmed
    ..Thus, our VSV system should be useful for investigating the functions of glycoproteins from highly pathogenic viruses or those incapable of being cultured in vitro...
  73. Yang Z, Delgado R, Xu L, Todd R, Nabel E, Sanchez A, et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science. 1998;279:1034-7 pubmed
  74. Weissenhorn W, Calder L, Wharton S, Skehel J, Wiley D. The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil. Proc Natl Acad Sci U S A. 1998;95:6032-6 pubmed
  75. Volchkov V, Volchkova V, Slenczka W, Klenk H, Feldmann H. Release of viral glycoproteins during Ebola virus infection. Virology. 1998;245:110-9 pubmed publisher
    ..The abundant shedding of soluble GP1 may play an important role in the immunopathology of Ebola hemorrhagic fever in experimentally and naturally infected hosts...
  76. M hlberger E, Weik M, Volchkov V, Klenk H, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol. 1999;73:2333-42 pubmed
    ..A chimeric minigenome, however, containing the EBOV leader and the MBGV trailer was encapsidated, replicated, transcribed, and packaged by both viruses...
  77. Scianimanico S, Schoehn G, Timmins J, Ruigrok R, Klenk H, Weissenhorn W. Membrane association induces a conformational change in the Ebola virus matrix protein. EMBO J. 2000;19:6732-41 pubmed publisher
    ..Such a conformational change induced by bilayer targeting may be a common feature of many viral matrix proteins and its potential inhibition may result in new anti-viral therapies...
  78. Baribaud F, Doms R, P hlmann S. The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination?. Expert Opin Ther Targets. 2002;6:423-31 pubmed publisher
    ..This article reviews the interaction of DC-SIGN and DC-SIGNR with HIV and Ebola, discusses the mechanism of DC-SIGN-mediated viral transmission and examines how this process could be inhibited by potential therapeutics...
  79. Lucht A, Grunow R, Otterbein C, M ller P, Feldmann H, Becker S. Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus. Med Microbiol Immunol. 2004;193:181-7 pubmed publisher
    ..Since the ELISA is able to detect even SDS-inactivated EBOV in spiked human sera, it could complement the existing diagnostic tools in the field and in routine laboratories where high containment facilities are not available...
  80. Irie T, Licata J, McGettigan J, Schnell M, Harty R. Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. J Virol. 2004;78:2657-65 pubmed
  81. Theriault S, Groseth A, Neumann G, Kawaoka Y, Feldmann H. Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res. 2004;106:43-50 pubmed publisher
    Using the infectious clone for Zaire ebolavirus, the functional specificity of viral proteins of the ribonucleoprotein complex in transcription/replication was investigated by substituting them with heterologous proteins derived from ..
  82. Earp L, Delos S, Park H, White J. The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol. 2005;285:25-66 pubmed
    ..We also briefly discuss the therapeutic potential of fusion inhibitors in treating viral infections...
  83. Ji X, Olinger G, Aris S, Chen Y, Gewurz H, Spear G. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol. 2005;86:2535-42 pubmed publisher
    ..These experiments demonstrated that MBL binds to filovirus envelope glycoproteins resulting in important biological effects and suggest that MBL can interact with filoviruses during infection in humans...
  84. Enterlein S, Volchkov V, Weik M, Kolesnikova L, Volchkova V, Klenk H, et al. Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol. 2006;80:1038-43 pubmed publisher
    ..In contrast, rescue of recombinant EBOV was not supported by EBOV VP30 containing a mutated Zn-binding domain...
  85. Johnson R, Bell P, Harty R. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J. 2006;3:31 pubmed publisher
    ..Overall, these findings indicate that major changes in morphology of VP40 VLPs were likely not responsible for enhanced budding of VP40 VLPs in the presence of GP, NP and/or VP35...
  86. John S, Wang T, Steffen S, Longhi S, Schmaljohn C, Jonsson C. Ebola virus VP30 is an RNA binding protein. J Virol. 2007;81:8967-76 pubmed publisher
    ..Thus, we show for the first time the direct interaction of EBOV VP30 with RNA and the importance of the N-terminal region for binding RNA...
  87. Wong A, Sandesara R, Mulherkar N, Whelan S, Chandran K. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol. 2010;84:163-75 pubmed publisher
    ..Altogether, our findings suggest that CatB cleavage is required to facilitate the triggering of viral membrane fusion by destabilizing the prefusion conformation of EBOV GP...
  88. Prins K, Delpeut S, Leung D, Reynard O, Volchkova V, Reid S, et al. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol. 2010;84:3004-15 pubmed publisher
    ..Moreover, these studies provide a framework for the development of antivirals targeting this critical EBOV virulence factor...
  89. Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, M hlberger E. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology. 2013;441:135-45 pubmed publisher
  90. Versteeg K, Menicucci A, Woolsey C, Mire C, Geisbert J, Cross R, et al. Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants. Sci Rep. 2017;7:9730 pubmed publisher
    b>Zaire Ebolavirus (ZEBOV) continues to pose a significant threat to human health as highlighted by the recent epidemic that originated in West Africa and the ongoing outbreak in the Democratic Republic of the Congo...
  91. Sasaki M, Setiyono A, Handharyani E, Rahmadani I, Taha S, Adiani S, et al. Molecular detection of a novel paramyxovirus in fruit bats from Indonesia. Virol J. 2012;9:240 pubmed publisher
    ..Phylogenetic analysis showed that these virus sequences were related to henipavirus or rubulavirus. This study indicates the presence of novel paramyxoviruses among fruit bat populations in Indonesia. ..
  92. Favier A, Gout E, Reynard O, Ferraris O, Kleman J, Volchkov V, et al. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein. J Virol. 2016;90:5256-5269 pubmed publisher
    ..In this study, we demonstrate that ficolin-1 interacts with the Zaire Ebola virus (EBOV) glycoprotein, and we characterized this interaction by surface plasmon resonance spectroscopy...